{"nctId":"NCT00424268","briefTitle":"Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)","startDateStruct":{"date":"2007-01"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":743,"armGroups":[{"label":"Roflumilast","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Roflumilast"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Roflumilast","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* History of COPD for at least 12 months prior to baseline visit and chronic productive cough for 3 months in each of the 2 years prior to baseline visit\n* FEV1/FVC ratio (post-bronchodilator) ≤ 70%\n* FEV1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted\n* Treated with tiotropium for at least 3 months before enrollment\n* At least 28 puffs of rescue medication during last week prior to randomization\n\nMain Exclusion Criteria:\n\n* COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)","description":"Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \\[L\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":"12"},{"groupId":"OG001","value":"-16","spread":"12"}]}]}]},{"type":"SECONDARY","title":"Post-bronchodilator FEV1","description":"Mean change from baseline during the treatment period in post-bronchodilator FEV1 \\[L\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":"12"},{"groupId":"OG001","value":"-7","spread":"11"}]}]}]},{"type":"SECONDARY","title":"COPD Exacerbation Rate (Moderate or Severe)","description":"Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \\[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.262","spread":null},{"groupId":"OG001","value":"0.342","spread":null}]}]}]},{"type":"SECONDARY","title":"Transition Dyspnea Index (TDI) Focal Score","description":"The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.1"},{"groupId":"OG001","value":"0.9","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Shortness of Breath Questionnaire (SOBQ) Total Score","description":"Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is \"not at all breathless\" and five is \"maximally breathless or too breathless to do the activity\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"0.7"},{"groupId":"OG001","value":"-0.7","spread":"0.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":374},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Diarrhoea","Weight decreased"]}}}